Company Profile

CIPLA LTD.

NSE : CIPLABSE : 500087ISIN CODE : INE059A01026Industry : Pharmaceuticals & DrugsHouse : Cipla
BSE901.905.9 (+0.66 % )
PREV CLOSE (Rs.) 896.00
OPEN PRICE (Rs.) 896.50
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 68820
TODAY'S LOW / HIGH (Rs.)878.45 913.05
52 WK LOW / HIGH (Rs.)706.45 1005
NSE901.85 5.5 (+0.61 % )
PREV CLOSE(Rs.) 896.35
OPEN PRICE (Rs.) 895.90
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 901.85 (10 )
VOLUME 1901039
TODAY'S LOW / HIGH(Rs.) 890.00 913.00
52 WK LOW / HIGH (Rs.)706.5 1005

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.01
Dividend Yield(%) 0.55
TTM EPS (Rs.) 32.85
P/E Ratio 27.46
Book Value (Rs.) 256.41
Face Value (Rs.) 2
MCap (Rs. in Mn) 727520.90
Price/Earning (TTM) 22.74
Price/Sales (TTM) 5.01
Price/Book (MRQ) 3.52
PAT Margin (%) 16.72
ROCE (%) 18.19
Incorporation Year : 1935

Management Info :

Y K Hamied - Chairman Umang Vohra - Managing Director

Registered Office :

Address : Cipla House,Peninsula Business Park,Ganpatrao Kadam Marg, Lower Parel,
Mumbai,
Maharashtra-400013

Phone : 022-24826000

Website : www.cipla.com

Registrar's Details : K FIN Technologies Pvt Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, Luxembourg, MCX
NEWS More
04Oct10-04-2021$Cipla, Eli Lilly and Company enter into strategic partnership in India Cipla, Eli Lilly and Company

Cipla and Eli Lilly and Company (India) -- wholly owned subsidiary of Eli Lilly and Company have entered into strategic partnership in India to enhance the reach of Lilly’s Diabetes products -- Humalog [Insulin Lispro I.P. (rDNA Origin) injection] and Trulicity (Dulaglutide).  As a part of this agreement, Lilly will transfer its rights in India to sell, promote and distribute the aforesaid two Lilly Diabetes products -- Humalog & Trulicity to Cipla, subject to all regulatory approvals.

Lilly will continue to maintain its existing operating model for the remaining portfolio of products. Cipla will leverage its capabilities and robust distribution strengths to engage healthcare professionals and expand access to these treatments for patients who need them.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla and Eli Lilly and Company (India) -- wholly owned subsidi..
22Sep09-22-2021$Cipla informs about issuance of duplicate certificate Cipla informs about issuance

Cipla has informed that its Registrar and Transfer Agent, KFin Technologies has received a request on 21st September 2021 for issuance of duplicate share certificate upon loss of original share certificates. The duplicate share certificates will be issued on completion of necessary formalities. The details of the shareholder and certificate are attached.

The above information is a part of company’s filings submitted to BSE.

Cipla has informed that its Registrar and Transfer Agent, KFin..
21Sep09-21-2021$Cipla gains on subscribing 5% stake in Swasth Digital Health Foundation Cipla gains on subscribing 5

Cipla is currently trading at Rs. 946.50, up by 7.45 points or 0.79% from its previous closing of Rs. 939.05 on the BSE.

The scrip opened at Rs. 931.10 and has touched a high and low of Rs. 947.75 and Rs. 931.10 respectively. So far 56799 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 997.20 on 30-Jun-2021 and a 52 week low of Rs. 706.45 on 10-Nov-2020.

Last one week high and low of the scrip stood at Rs. 964.80 and Rs. 930.05 respectively. The current market cap of the company is Rs. 76035.17 crore.

The promoters holding in the company stood at 36.72%, while Institutions and Non-Institutions held 41.07% and 22.21% respectively.

Cipla has subscribed to 5% equity shares (on a fully diluted basis) of Swasth Digital Health Foundation, a not-for-profit organisation. The company aims to leverage digital technologies and build healthcare tech infrastructure.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla is currently trading at Rs. 946.50, up by 7.45 points or..
20Sep09-20-2021$Cipla subscribes 5% stake in Swasth Digital Health Foundation Cipla subscribes 5% stake in

Cipla has subscribed to 5% equity shares (on a fully diluted basis) of Swasth Digital Health Foundation, a not-for-profit organisation. The company aims to leverage digital technologies and build healthcare tech infrastructure.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla has subscribed to 5% equity shares (on a fully diluted ba..
18Sep09-18-2021$Cipla informs about analyst meet Cipla informs about analyst

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Cipla has informed that it enclosed the schedule of Analyst/ Institutional Investor Meetings with the Company to be held on 20th and 21st September 2021. The schedule of the meetings is subject to change and the change may occur due to exigencies on the part of Investor/ Company.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 30 of the Securities and Exchange Board..
Financials More
Rs. in Millions
QTR Jun 21 ANNUAL 21
Net Profit7917.724682.8
Gross Profit 10801.7 33506.6
Operating Profit 12251.539518.4
Net Sales 40174.1139005.8
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Torrent Pharma (BSE)
 3084.55 (3.91%)
M.Cap ( in Cr)
52193.28
NGL Fine-Chem (BSE)
 2554.25 (4.38%)
M.Cap ( in Cr)
1578.02
Venus Remedies (BSE)
 502.90 (14.73%)
M.Cap ( in Cr)
672.23
Kwality Pharma (BSE)
 913.50 (5.00%)
M.Cap ( in Cr)
947.87
Dr. Reddy's Lab (BSE)
 4675.45 (0.85%)
M.Cap ( in Cr)
77798.93
Shareholding Pattern More
FI/BANKS/INSURANCE 4.18 %
PROMOTERS 36.12 %
NON-INSTITUTION 18.05 %
MUTUAL FUNDS/UTI 13.23 %
FII 0.01 %
GOVERNMENT 0 %
F & O Quotes